This abstract is assigned to sessions
| Presentation preference | Oral presentation |
| Title | Long term efficacy of infliximab in refractory uveoretinitis associated with Behçet's disease |
| Accept poster if oral is not possible ? | Yes |
| Purpose | To evaluate the long term efficacy of infliximab (IFX) in patients with refractory uveoretinitis associated with Behçet’s disease (BD). |
| Methods | Clinical records of 16 patients treated with IFX for at least 5 years (1 woman, 15 men) were retrospectively reviewed. The main outcomes analyzed were frequency of ocular inflammatory attacks, the Behcet’s disease ocular attack score 24 (BOS24), best-corrected visual acuity (BCVA), and adverse effects. |
| Results | The median follow-up on IFX was 125 months (range 71-140 months), 16 patients were followed for > 5 years and 10 patients for > 10 years. Mean frequency of attacks and BOS24 decreased significantly over 10 years compared to the baseline 1-year period prior to IFX use. Percentage of eyes with a BCVA ≥ 1.0 was 47% at baseline, 59% at 5 years and 70% at 10 years, whereas percentage of eyes with a BCVA ≤ 0.1 was 19% at baseline, 19% at 5 years and 10% at 10 years. IFX therapy was stopped in one patient due to colon cancer at 10 years after initiation of IFX. IFX therapy was discontinued in 4 patients showing complete remission of uveoretinitis over the IFX treatment period, with no recurrent inflammation observed over a median follow-up of 49 months. |
| Conclusion | IFX reduced the mean frequency of ocular attacks and the BOS24 score in a sustained manner over 10 years of treatment in BD patients. IFX appeared to be effective in maintaining good visual acuity in BD patients over the long term. |
| Conflict of interest | Yes |
| Details of conflicting interests | Hiroshi Keino: lecture fees from Santen Pharma Corporation, Alcon Pharma Japan, Nikon Healthcare Japan, Senju Pharmaceutical Corporation; grant and lecture fees from Mitsubishi Tanabe Pharma.
Annabelle A. Okada: consultant to AbbVie Japan, Astellas Pharma Japan, Bayer AG, Daiichi Sankyo; lecture fees from Alcon Pharm Japan, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Santen Pharmaceutical Corporation, Senju Pharmaceutical Corporation; grant support from Alcon Pharma Japan, Bayer Yakuhin, Mitsubishi Tanabe Pharma. |
Author 1
| Last name | KEINO |
| Initials of first name(s) | H |
| City | Tokyo |
| Country | Japan |
Author 2
| Last name | Nakayama |
| Initials of first name(s) | M |
| City | Tokyo |
| Country | Japan |
Author 3
| Last name | Watanabe |
| Initials of first name(s) | T |
| City | Tokyo |
| Country | Japan |
Author 4
| Last name | Ando |
| Initials of first name(s) | Y |
| City | Tokyo |
| Country | Japan |
Author 5
| Last name | Abe |
| Initials of first name(s) | S |
| City | Tokyo |
| Country | Japan |
Author 6
| Last name | Hayashi |
| Initials of first name(s) | I |
| City | Tokyo |
| Country | Japan |
Author 7
| Last name | Fukuoka |
| Initials of first name(s) | K |
| City | Tokyo |
| Country | Japan |
Author 8
| Last name | Komagata |
| Initials of first name(s) | Y |
| City | Tokyo |
| Country | Japan |
Author 9
| Last name | Okada |
| Initials of first name(s) | A |
| City | Tokyo |
| Country | Japan |
